Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease

Larissa Lobo Torres1, Nathalia Barbosa Quaglio, Gisele Tavares de Souza

  • 1Department of Clinical Chemistry and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.

Insights

Oxidative stress and lipid peroxidation increase in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Antioxidant defenses decrease in MCI and AD, correlating with cognitive decline.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Gerontology

Background:

  • Oxidative stress is linked to aging and Alzheimer's disease (AD).
  • Limited data exists on oxidative stress in mild cognitive impairment (MCI), a precursor to AD.
  • Investigating oxidative stress markers and antioxidant enzyme activities in MCI is crucial.

Purpose of the Study:

  • To assess plasma malonaldehyde (MDA) levels, a lipid peroxidation marker.
  • To determine erythrocyte antioxidant enzyme activities (catalase, glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S-transferase (GST)).
  • To evaluate the GR/GPx activity ratio and its relation to cognitive function (MMSE) in MCI, AD, and healthy controls.

Main Methods:

  • Cross-sectional study comparing 33 MCI, 29 mild AD, and 26 healthy elderly subjects.
  • Plasma MDA levels were measured.
  • Erythrocyte activities of catalase, GPx, GR, and GST were assayed; GR/GPx ratio calculated.
  • Cognitive performance assessed using the Mini Mental State Examination (MMSE).

Main Results:

  • AD patients exhibited higher MDA than MCI and controls; MCI patients had higher MDA than controls.
  • GR activity was lower in MCI and AD patients compared to controls.
  • GR/GPx ratio was highest in controls, intermediate in MCI, and lowest in AD patients.
  • MMSE scores negatively correlated with MDA and positively with GR/GPx ratio in AD patients.

Conclusions:

  • Elevated lipid peroxidation and diminished antioxidant capacity are evident early in cognitive decline.
  • These oxidative stress markers may serve as indicators for MCI and progression to AD.
  • Further research is warranted to explore therapeutic interventions targeting oxidative stress in cognitive disorders.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...